XML 53 R37.htm IDEA: XBRL DOCUMENT v3.25.4
Stockholders Equity (Tables)
 12 Months Ended
Dec. 31, 2025
Stockholders Equity [Line Items]  
Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders

As of December 31, 2025, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders:

 

Warrant  Issuance Date  Expiration
Date		  Exercise
Price
Per Share		   Number of
Shares of
Common Stock
Underlying
Warrants		 
2021 Registered Direct Offering Warrants  July 28, 2021  January 28, 2027   950.00    14,808 
Merger Warrants  March 15, 2024  January 28, 2027   950.00    11,404 
Private Placement Warrants  March 15, 2024  July 9, 2026   43.91    203,444 
Registered Pre-Funded Warrants  February 25, 2025  April 21, 2030   0.0019    42,381 
Private Pre-Funded Warrants  February 25, 2025  April 21, 2030   0.0019    46,232 
Common Warrants  February 25, 2025  April 21, 2030   17.68    312,503 
Inducement Warrants  February 25, 2025  April 21, 2030   17.68    366,087 
A&R Warrants  February 25, 2025  April 21, 2030   0.0019    157,603 
               1,154,462 

As of December 31, 2025, and 2024, the Company had the following outstanding compensation related warrants to purchase Common Stock as follows:

 

Warrant  Issuance Date  Expiration Date   Exercise Price Per Share   Number of Shares of Common Stock Underlying Warrants 
Private Warrants issued to scientific founders*  November 27, 2017 
-
    
-
    16 
Landlord Warrants**  March 15, 2024  January 28, 2027    950.00    1,316 
Agents Warrants  March 15, 2024  July 9, 2026    43.91    50,126 
                51,458 

 

 * In November 2017, BiomX Israel issued 298 warrants to its founders. The warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction. The warrants did not expire as a result of the Recapitalization Transaction and have no exercise price. The Merger Agreement as described in note 1C does not apply for such M&A transaction as defined in the grant agreement.
** See Note 5
Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model

The fair value of each option was estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions:

 

   2025   2024 
         
Underlying value of Common Stock ($)   10.22    68.97 
Exercise price ($)   10.22    68.97 
Expected volatility (%)   110.5    112.6 
Expected terms of the option (years)   6.11    6.11 
Risk-free interest rate (%)   4.12    4.14 
Schedule of Options Granted to Purchase the Company’s Common Stock Under the Company’s Stock Option Plans

A summary of options granted to purchase the Company’s Common Stock under the Company’s stock option plans are as follows:

 

   For year ended
December 31, 2025		 
   Number of Options   Weighted average exercise price   Aggregate intrinsic value 
             
Outstanding at the beginning of period   105,525   $77.71   $  15 
Granted   63,716    10.22      
Forfeited   (15,085)   56.88      
Expired   (3,051)   58.71      
Exercised   (718)  $0.79      
Outstanding at the end of period   150,387    51.94   $
-
 
Exercisable at end of period   41,096    92.45      
Weighted average remaining contractual life – years as of December 31, 2025   8.21           
Schedule of Stock-Based Payment Expenses

The following table sets forth the total stock-based payment expenses resulting from options, RSUs and warrants granted, included in the consolidated statements of operations:

 

   Year ended
December 31,		 
   2025   2024 
         
Research and development expenses, net   711    600 
General and administrative   1,380    1,248 
    2,091    1,848 
Agents Warrants [Member]  
Stockholders Equity [Line Items]  
Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model

The Company determined the fair value of the Agents Warrants using the Black-Scholes model as of March 5, 2024. The main assumptions used are as follows:

 

Underlying value of Common Stock ($)   43.91 
Exercise price ($)   43.91 
Expected volatility (%)   100.6 
Expected terms (years)   2.32 
Risk-free interest rate (%)   4.4